Sinopharm Group Co Ltd
HKEX:1099

Watchlist Manager
Sinopharm Group Co Ltd Logo
Sinopharm Group Co Ltd
HKEX:1099
Watchlist
Price: 20.56 HKD 0.49% Market Closed
Market Cap: 64.2B HKD

Sinopharm Group Co Ltd
Gain/Loss on Disposition of Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sinopharm Group Co Ltd
Gain/Loss on Disposition of Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gain/Loss on Disposition of Assets CAGR 3Y CAGR 5Y CAGR 10Y
Sinopharm Group Co Ltd
HKEX:1099
Gain/Loss on Disposition of Assets
ÂĄ81.3m
CAGR 3-Years
35%
CAGR 5-Years
23%
CAGR 10-Years
17%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Medicines Corp Ltd
SSE:600511
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Huadong Medicine Co Ltd
SZSE:000963
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Accord Medicines Corp Ltd
SZSE:000028
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sinopharm Group Co Ltd
Glance View

Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.

Intrinsic Value
89.47 HKD
Undervaluation 77%
Intrinsic Value
Price

See Also

What is Sinopharm Group Co Ltd's Gain/Loss on Disposition of Assets?
Gain/Loss on Disposition of Assets
81.3m CNY

Based on the financial report for Jun 30, 2025, Sinopharm Group Co Ltd's Gain/Loss on Disposition of Assets amounts to 81.3m CNY.

What is Sinopharm Group Co Ltd's Gain/Loss on Disposition of Assets growth rate?
Gain/Loss on Disposition of Assets CAGR 10Y
17%

Over the last year, the Gain/Loss on Disposition of Assets growth was -75%. The average annual Gain/Loss on Disposition of Assets growth rates for Sinopharm Group Co Ltd have been 35% over the past three years , 23% over the past five years , and 17% over the past ten years .

Back to Top